CRB EPIGENETEC
CRB EPIGENETEC is recorded as a service provider in 5 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 5 of 5 trials · Latest update first
PRODIGE 88 (FFCD 2002) CIRCULATE MRD PAC: A phase III multicentric, open-label, randomized study of chemotherapy in patients with positive ctDNA after surgery and adjuvant chemotherapy for high-risk stage II and stage III colorectal cancer
Sponsor Centre Hospitalier Universitaire De Dijon
- Start (EU)
- Latest update
- Estimated end
- Not reported
ENGIC 06 (PRODIGE 114) – FFCD 2401 – FRUQUITAS Randomized phase III trial to compare trifluridine/tipiracil + Fruquintinib versus trifluridine/tipiracil alone for metastatic oeso-gastric adenocarcinoma.
Sponsor Fondation Franc.Cancerologie Digestive
- Start (EU)
- Latest update
- Estimated end
- Not reported
PRODIGE 70 - CIRCULATE - CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II
Sponsor Centre Hospitalier Universitaire De Dijon
- Start (EU)
- Latest update
- Estimated end
- Not reported
PRODIGE 34 - ADAGE: Randomised phase III study evaluating adjuvant chemotherapy after resection of stage III colon adenocarcinoma in patients aged 70 and older
Sponsor Fondation Franc.Cancerologie Digestive
- Start (EU)
- Latest update
- Estimated end
- Not reported
PRODIGE 115 (FFCD 2406) ULYSSE : A phase II, open-label, non-comparative, randomized study of second-line doublet chemotherapy (FOLFOX or FOLFIRI) plus Fruquintinib versus doublet chemotherapy (FOLFOX or FOLFIRI) plus Bevacizumab in metastatic colorectal cancer
Sponsor Fondation Franc.Cancerologie Digestive
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for CRB EPIGENETEC?
The 2026-10-09 snapshot links CRB EPIGENETEC to 5 distinct CTIS trials. Recorded services include Laboratory services, sample archiving. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for CRB EPIGENETEC?
The most frequently recorded therapeutic areas are Gastroenterology, Solid Tumor Oncology. Recorded phases include Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to CRB EPIGENETEC conducted?
The linked trials record locations in 4 countries, including France, Belgium, Germany, Spain. These are trial locations, not confirmed office locations or countries where CRB EPIGENETEC delivered services.
What can this page tell me about CRB EPIGENETEC's trial experience?
Browse 5 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under CRB EPIGENETEC. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- CRB EPIGENETEC